Evidence map›Paper›PMID 40243905›Full record

ArticleInternational journal of molecular sciences2025

RBM17 Promotes the Chemoresistance of Oral Squamous Cancer Cells Through Checkpoint Kinase 1.

Miyuka Nakahara, Ryosuke Arai, Isao Tokuoka, Kazuhiro Fukumura, Akila Mayeda, Masakazu Yashiro, Hirokazu Nakahara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Miyuka NakaharaDepartment of Oral and Maxillofacial Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Ryosuke AraiDepartment of Oral and Maxillofacial Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.ORCID 0009-0008-3905-9962
Isao TokuokaDepartment of Oral and Maxillofacial Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.ORCID 0009-0008-4860-9508
Kazuhiro FukumuraOncology Innovation Center, Fujita Health University, Toyoake 470-1192, Japan.ORCID 0000-0002-3491-4500
Akila MayedaOncology Innovation Center, Fujita Health University, Toyoake 470-1192, Japan.ORCID 0000-0002-9562-550X
Masakazu YashiroMolecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.ORCID 0000-0001-5743-7228
Hirokazu NakaharaDepartment of Oral and Maxillofacial Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common types of cancer in the head and neck region. In advanced stages of OSCC, chemotherapy is commonly used for treatment, despite some cancer cells having low sensitivity to anticancer drugs. We focused on RBM17/SPF45 as an essential drug-sensitizing factor in the context of malignant cells acquiring chemoresistance. Here, we demonstrate how RBM17 affects anticancer drug resistance in OSCC and we suggest the possible mechanism underlying its effects. After exposing oral cancer cell lines to fluorouracil (5-FU) and cisplatin, but not paclitaxel, the gene and protein expression of RBM17 increased. We found that siRNA-mediated

Indexed as

Carcinoma, Squamous CellCheckpoint Kinase 1Drug Resistance, NeoplasmMouth NeoplasmsRNA-Binding ProteinsAntineoplastic AgentsCell Line, TumorCisplatinFluorouracilGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsCheckpoint Kinase 1CHEK1 protein, humanCisplatinFluorouracilRNA-Binding ProteinschemoresistancechemotherapyChk1oral squamous cell carcinomaRBM17/SPF45

Identifiers

PMID40243905
PMCPMC11989059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.